Investor Presentaiton
46
Investor presentation
Full year 2022
Novo NordiskⓇ
Semaglutide 2.0 mg s.c. and high dose oral sema hold potential to
bring patients needing treatment intensification to target
Phase 3 trial, SUSTAIN FORTE, completed and label application
approved in the US and the EU
Phase 3 trial with oral semaglutide 25 mg and 50
mg in T2D has been initiated
Semaglutide 50 mg
Estimand
Trial product estimand
Treatment policy estimand
Once-weekly
2.0 mg
1.0 mg
2.0 mg
1.0 mg
Semaglutide 25 mg
semaglutide
HbA1c
2.2%*
1.9%
2.1%*
1.9%
reduction
Semaglutide 14 mg
Body weight
6.9*
6.0
6.4
5.6
Dose escalation
Maintenance
reduction (kg)
Primary endpoint
after 52 weeks
HbA1c < 7.0%¹
68%
58%
68 weeks on-treatment
5-weeks
follow-up
Efficacy: Semaglutide 2.0 mg s.c. showed superior HbA1c reduction with more
patients reaching target¹ versus semaglutide 1.0 mg s.c.
Safety: Semaglutide 2.0 mg appeared to have a safe and well-tolerated profile
Gastrointestinal adverse events were similar for semaglutide 2.0 mg
Nausea rates around 15%
Treatment discontinuation rates below 5%
Label expansion application approved in the US and the EU
Objective: Trial will assess efficacy for patients in need of improved outcomes
Primary endpoint: Confirm superiority of semaglutide 25 mg and 50 mg once-daily
versus oral semaglutide 14 mg on HbA1c reduction
1 ADA recommended treatment target
*Statistically significant
S.c.: subcutaneous; Sema: Semaglutide; T2D: Type 2 diabetesView entire presentation